AbbVie Inc. (ABBV)
| Market Cap | 310.27B |
| Revenue (ttm) | 55.53B |
| Net Income (ttm) | 5.08B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.87 |
| PE Ratio | 61.18 |
| Forward PE | 14.64 |
| Dividend | $6.56 (3.74%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 17,496,344 |
| Open | 171.79 |
| Previous Close | 171.52 |
| Day's Range | 170.66 - 176.80 |
| 52-Week Range | 153.09 - 207.32 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 207.45 (+18.15%) |
| Earnings Date | Jan 31, 2025 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.82 billion, a decrease of -59.09%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $207.45, which is an increase of 18.15% from the latest price.
News
Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65
Dividend investing can provide reliable income and peace of mind in retirement. I share five standout picks perfect for a retirement-ready portfolio. These stocks offer strong yields, consistent growt...
My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys
In November, I invested $1,400 primarily in Business Development Companies, boosting my yearly dividend income by $148, with a YTD total exceeding $1,400. My portfolio achieved all-time highs, driven ...
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo; Topic is Pharmacokinetics of AL001.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors
AbbVie offers a compelling investment opportunity after a recent price drop, combining dividend income, value, and growth potential driven by a strong drug portfolio and pipeline. Robust growth in imm...
AbbVie Enters Oversold Territory
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoim...
Buy 6 December Dividend Kings But Watch 22 With 'Safer' Dividends
"A Dividend King [is] a stock with 50 or more consecutive years of dividend increases." - suredividend.com. 53 Divided Kings, screened as of December 11, 2024, represented all eleven Morningstar Secto...
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
ATLANTA--(BUSINESS WIRE)---- $ABBV #5_clinical_trials_to_start_2025--Alzamend Neuro Reports 2nd Quarter 2025 Financial Results and Provides Update on Clinical Programs; Cash of $4.1 million as of Octo...
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. has rebounded from setbacks with a strong pipeline, including the promising Parkinson's drug Tavapadon, which shows blockbuster potential. Key growth drivers like SKYRIZI and RINVOQ are bo...
AbbVie Completes Acquisition of Aliada Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R...
Dividend Income Summary: Lanny's November 2024 Summary
Investing in dividend stocks allows you to earn dividend income, the best passive income stream. The power of compounding and dividend reinvestment is a wonderful component to the portfolio. All of th...
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results ...
AbbVie's third successful Parkinson's trial sets the stage for an eventful 2025
AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson's disease on Monday and said it's on track to seek approval for the drug from the Food and Drug Administr...
Don't Miss The Dividend Train: 2 Top Buys To End 2024
Time in the market generally beats timing the market. This can be enhanced by buying low and selling high. Here's how. Being an active investor, I believe that timing individual equities can complemen...
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie said on Monday its experimental drug to treat Parkinson's disease met the main goal in a late-stage study.
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III...
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys -CLL is one ...
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated resu...
Calls of the Day: Toast, Abbvie, Berkshire Hathaway
The Investment Committee debate the latest Calls of the Day.
AbbVie Inc. (ABBV) Citi's 2024 Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) Citi's 2024 Global Healthcare Conference Call December 3, 2024 10:15 AM ET Company Participants Jeffrey Stewart - Executive Vice President and Chief Commercial Officer Roopal ...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Forget Big Tech - I'll Take Dividend Stalwarts Any Day
Big Tech dominates markets but faces risks like slowing growth, AI dependency, and inflated valuations. Dividend stalwarts offer a safer, smarter alternative. Dividend stocks, like those in VYM and SC...